Christophe Weber

Weber, a French national, orchestrated the transformative $62 billion acquisition of Irish-headquartered Shire in 2019 — the largest-ever foreign acquisition by a Japanese company — which catapulted Takeda from a primarily Japan-focused pharma into a global biopharma leader. The Shire acquisition brought Takeda leadership positions in rare diseases (particularly rare hematology with hemophilia treatments), plasma-derived therapies (immunoglobulins, albumin), gastroenterology (Entyvio for inflammatory bowel disease — one of the world's best-selling biologics), and neuroscience. Takeda also maintains oncology programs and a growing pipeline. Post-acquisition, Weber executed a massive portfolio transformation — divesting over $15 billion in non-core assets to reduce debt and sharpen focus on innovative biologics. Key stock drivers include Entyvio sales trajectory and biosimilar competition timeline, plasma-derived therapy demand and pricing, rare disease pipeline progress, pipeline catalysts and new launches, debt reduction progress, yen exchange rate impact on earnings, and competition in GI, oncology, and rare disease markets.